Summary:The disease-free survival of patients with myeloma and severe renal failure after high-dose melphalan and autologous stem cell rescue is similar to those with normal renal function at the time of the autograft. However, recovery of renal function after intensive treatment is uncommon and patients with end-stage renal failure continue to be dialysis-dependent. We report two patients with myeloma who required regular haemodialysis from diagnosis, but became dialysis-independent after a high-dose melphalan autograft. Thus, in some patients, renal function may be partially salvageable despite the requirement for dialysis at the time of autografting. Bone Marrow Transplantation (2002) 30, 471-473. doi:10.1038/sj.bmt.1703713 Keywords: myeloma; end-stage renal failure; stem cell transplantation There is emerging evidence that patients with myeloma and impaired renal function including those on haemodialysis should be offered treatment with high-dose melphalan (HDMel) and autologous stem cell rescue. 1,2 While renal function can improve after conventional chemotherapy in some patients with renal failure at diagnosis, 3 no significant improvement in renal function has been observed after HDMel. It has been suggested that the renal outcome after HDMel may be related to the type of paraprotein, as well as duration of myeloma. 1 We report two patients with endstage renal failure who became dialysis-independent after treatment with HDMel. Our experience indicates the potential for recovery of renal function after autografting even in patients requiring dialysis. Further studies on mechanisms that cause progressive and irreversible renal damage in myeloma may help identify patients in whom HDMel can potentially restore renal function. Patients Patient 1A 52-year-old male was investigated for a 10-week history of left-sided chest pain. X-rays revealed lytic lesions in the ribs and biopsy was consistent with plasmacytoma. He was anaemic (Hb 7.6 g/l), hypercalcemic (Ͼ3 mmol/l) and in renal failure (creatinine 690 mol/l). There was no serum paraprotein, but light chains were detected in the urine (75.49 g/gCr). The serum 2-microglobulin (2-M) level was 15.3 and plasma cell infiltrate in the marrow was 25% (stage 3B myeloma). Ultrasound of the kidneys was normal and renal biopsy showed distortion of most renal tubules by casts, surrounded by giant cells. These tubular defects suggested myeloma kidney.A thrice weekly schedule of haemodialysis was started to treat acidosis and volume overload, and the patient received his first cycle of VAD chemotherapy (repeated every 3 weeks) 6 days after the diagnosis. The urinary paraprotein declined to 20.29 g/gCr after two cycles of VAD and re-staging investigations after four cycles of VAD indicated a decrease in marrow plasma cell infiltrate (5%). At this stage his serum 2-M and creatinine were 38.7 and 525 mol/l, respectively, and he continued on haemodialysis three times a week. Following the fifth cycle of VAD, peripheral blood stem cells were mobilized with G-CSF (10 g/kg/day...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.